flutamide has been researched along with Cancer of Ovary in 7 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flutamide has to be considered ineffective in patients extensively pretreated with chemotherapy, and it is not devoid of side-effects." | 2.67 | Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. ( Guastalla, JP; Rao, BR; Renard, J; Tumolo, S; van der Burg, ME; Vermorken, JB, 1994) |
| "Roles of androgens in testicular tumor development have been investigated in our previous studies using double-mutant mice lacking inhibins and carrying the null testicular feminization (tfm) mutation of the androgen receptor." | 1.32 | Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. ( Agno, JE; Burns, KH; Chen, L; Haupt, B; Korach, KS; Matzuk, MM; Ogbonna, SC, 2003) |
| "Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels." | 1.31 | Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. ( Brown, TJ; Evangelou, A; Jindal, SK; Letarte, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruessner, C | 1 |
| Gruessner, A | 1 |
| Glaser, K | 1 |
| AbuShahin, N | 1 |
| Zhou, Y | 1 |
| Laughren, C | 1 |
| Wright, H | 1 |
| Pinkerton, S | 1 |
| Yi, X | 1 |
| Stoffer, J | 1 |
| Azodi, M | 1 |
| Zheng, W | 1 |
| Chambers, SK | 1 |
| Burns, KH | 1 |
| Agno, JE | 1 |
| Chen, L | 1 |
| Haupt, B | 1 |
| Ogbonna, SC | 1 |
| Korach, KS | 1 |
| Matzuk, MM | 1 |
| Wang, Y | 1 |
| Yang, J | 1 |
| Gao, Y | 1 |
| Dong, LJ | 1 |
| Liu, S | 1 |
| Yao, Z | 1 |
| van der Vange, N | 1 |
| Greggi, S | 1 |
| Burger, CW | 1 |
| Kenemans, P | 1 |
| Vermorken, JB | 2 |
| Tumolo, S | 1 |
| Rao, BR | 1 |
| van der Burg, ME | 1 |
| Guastalla, JP | 1 |
| Renard, J | 1 |
| Werner, A | 1 |
| Aichberger, A | 1 |
| Krebs, D | 1 |
| Evangelou, A | 1 |
| Jindal, SK | 1 |
| Brown, TJ | 1 |
| Letarte, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer[NCT00699907] | Phase 2 | 127 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CSF-1 levels were measured by immunohistochemistry (IHC).~The modified H-Score assess extent of nuclear immunoreactivity applicable to steroid receptors.~The modified H-scores total range is 0-300. A lower modified H-score indicates weakly staining nuclei. A higher modified H-score indicated strongly staining nuclei.~This applies to all measures." (NCT00699907)
Timeframe: Surgery
| Intervention | Modified H-Score (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 130 |
| Low Risk Arm | 50 |
CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 50 |
| Low Risk Arm | 0 |
CSF-1 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 40 |
| Low Risk Arm | 35 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 15 |
| High Risk Arm | 160 |
| Low Risk Arm | 75 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 40 |
| Low Risk Arm | 20 |
CSF-1R levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 20 |
| High Risk Arm | 40 |
| Low Risk Arm | 53 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 5 |
| High Risk Arm | 60 |
| Low Risk Arm | 10 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 0 |
| High Risk Arm | 55 |
| Low Risk Arm | 0 |
ErbB4 levels were measured by immunohistochemistry (IHC). (NCT00699907)
Timeframe: Surgery
| Intervention | Histo-score (H-Score) (Median) |
|---|---|
| Treatment Arm | 10 |
| High Risk Arm | 90 |
| Low Risk Arm | 30 |
2 trials available for flutamide and Cancer of Ovary
| Article | Year |
|---|---|
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Topics: Adult; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Area Under Curve; Biomarkers, | 2014 |
Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flutamide; Humans; Middle Aged; Ovari | 1994 |
5 other studies available for flutamide and Cancer of Ovary
| Article | Year |
|---|---|
Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis.
Topics: Androgens; Animals; Body Weight; Cachexia; Cyclin D2; Cyclins; Estrogen Receptor alpha; Estrogen Rec | 2003 |
Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma.
Topics: Androgen Receptor Antagonists; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; | 2007 |
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Es | 1995 |
[Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells?].
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Cell Line; C | 1996 |
Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells.
Topics: Dihydrotestosterone; Down-Regulation; Female; Flutamide; Gene Expression Regulation; Humans; Ovarian | 2000 |